









**March 2013** 



# **2012 Full-Year results**

Dr Jean-Claude Marian M.D. - Chairman

**Yves Le Masne –** Chief Executive Officer

Jean-Claude Brdenk - Deputy Chief Executive Officer

**Steve Grobet** - Investor Relations Officer

## **Content**

1. Regulatory environment



3. ORPEA network

4. 2012 Full-Year results

5. Strategy and outlook

















# **Overview**

# **ORPEA:** European leader in global dependency care








European leader in global Dependency care









# 2002 - 2012: 10 years of growth and value creation





# Net profit(€m) 100 75 X 9.2 50 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012





# **Execution of the group's stated strategy**

#### **STRTEGIC TARGETS**

#### **ACHIEVEMENTS**

Selective acquisition policy



- Increase of the network of **3,660 beds** since start of 2012
- Acquisition and integration of Artevida in Spain and Medibelge in Belgium

2012

Improvement in profitability



- \* EBITDAR margin: +60 bp
- \* Recurring EBIT margin: +40 bp (13.6%)

Financial flexibility and property sale



- \*\* Property sale: €300m
- \* Reduction in debt ratio

Attractive dividend policy



- Froposed dividend per share: €0.60 (+20%)
- Payout ratio of net profit: 33%






# **Regulatory environment**

## **Daily rate in France**

#### **Nursing Homes**


#### **Post-acute and Psychiatric facilities**



#### **CARE & ACCOMMODATION**

(in a double bedroom): 70%

Mational Health Insurance



# OTHER SUPPLEMENTS INCL. SINGLE PRIVATE ROOM: 30%

Directly paid for by patient and/or private health insurance



## **ORPEA positioning in the French healthcare system**

## **ORPEA positioning**

	Acute care facilities	Post-acute, Rehab. & Psy facilities	Nursing homes
Paid by National Health Insurance	Care + Accomodation <sup>1</sup>	Care + Accomodation <sup>1</sup>	Care only
Daily cost / patient	€500 - €800	~€150	~€20
% of total daily price	86% to 91%	67%	20%
Paid by Private patient	Single private room	Single private room	Accommodation & Food
Daily cost / patient	~ €70	~ €70	~ €75
% of total daily price	14% to 9%	33%	70%

<sup>&</sup>lt;sup>1</sup> in semi private room

- **DGOS\* study** (Nov. 2011): 10% of medical and surgical beds not filled appropriately **(25,000 patients)** 
  - Additional cost to the health insurance system: €2bn p.a.
  - Solution: develop more beds in post-acute and rehabilitation care facilities or in long-term care facilities
- \* Enhance cooperation between general practitioners, hospitals, nursing homes and post-acute care facilities



# Challenges posed by population ageing in France

# Increase in the population of the very elderly




# Higher investment requirements



# Increased spending linked to the loss of autonomy

# Trend in nbr of people aged over 85 (million)



Source: INSEE, Population forecasts by 2060

	Nbr of beds	Cost (excl. land)
Beds to be created (next 5 to 10 years)	20,000 to 30,000	€1.6 to €2.4bn
Beds to be "refurbished" (CNSA)	116,000	€11.7bn

- Spending on loss of autonomy:€34bn (including €24bn by public authorities)
- Additional spending: €8.5bn to €10.3bn out to 2040

# OPPORTUNITIES FOR THE ECONOMY

- \* Creation of 350,000 jobs in the care for the elderly sector
- Boost to the construction sector: 1 nursing home = €10m in construction sales
- \* Emergence of the gerontological technology sector

# LEGITIMATE OPPORTUNITIES FOR THE PRIVATE SECTOR

- Capacity to invest and create jobs
- Expertise in providing training for these jobs
- Know-how in construction and restructuring
- \* Still limited in size: 20% of nursing home beds in France



## French bill on adapting society to the ageing phenomenon

# Imperatives of the Reform

- \* State's and local communities' limited financial resources (investment and operating budget)
- Financing based on national solidarity and individual responsibility (F. Hollande)
- Focus on an integrated approach to the loss of autonomy and ageing

### 3 goals: Prevention Adaptation Support

- **Prevention**: identify and deal more effectively with vulnerabilities earlier before people lose their autonomy
- \* Adaptation: society must adapt to an older population–housing, transport, urban planning, etc.
- Support to be provided when people lose their autonomy: development of in-home services, introduction of departmental autonomy centres

#### **Action by ORPEA**

Prevention: Age Well days, help for carers, promotion of physical activity,

Facilities proactive in building local gerontological networks

# Projects for the nursing home sector

- 80% of beds are in the public and non-profit sector, and thus controlled by the public authorities
- 5 Objective: increase the solvency of the middle classes
- \* Assumption: concentrate the various different forms of assistance and maximise their impact



Real determination to put together integrated solutions for ageing subject to budget constraints







# **Last development**

## **ORPEA-DOMIDOM:** a productive partnership



Win-win partnership

- **Objective: facilitate continuity of care** between home, post-acute & rehabilitation facilities and nursing homes
- \* Construction of an **innovative integrated range of solutions** covering every stage of dependence

**Combination** of expertise

- \* Sharing of skills and training by teams
- \* Sharing of best practices: introduction of **common Quality processes**

Successful operational implementation

- Introduction of **DOMIDOM units** in ORPEA's **post-acute & rehabilitation care** facilities
- **DOMIDOM services** to be offered in **nursing homes**
- \* Creation of new DOMIDOM branches in ORPEA facilities (Paris, Lyon, Royan, etc.)



Productive partnership and cross fertilisation of capacities and services



## An innovative telemedecine project

- **Origin: call for projects launched by the Paris region health authority**
- **Idea: improve emergency treatment arrangements in nursing homes** 
  - Medical presence in nursing homes via a virtual medical practice
  - Use specialised medical resources of post-acute & rehabilitation and psychiatric facilities to provide a remote medical opinion
- 5 Objectives: deliver better care and medical treatment
  - Avoid use of emergency services and reduce hospital admissions
  - Reduce movements by residents in nursing homes
  - Help to make spending by French health insurance more efficient
- \* A few examples
  - Electrocardiogram analysed by cardiologists in post-acute & rehabilitation care facilities
  - Psychiatrist consultation
- <sup>₹</sup> Roll-out
  - Trials at a nursing home and group clinic from May 2013 onwards
  - Open up the telemedicine concept to other non-Group facilities



An innovative solution to improve the well-being of residents and boost the efficiency of public spending






## Flanders: European region with strong needs


Strongest increase of people aged over 85:

Up 71% between 2010 and 2030

#### $\underline{\textbf{Growth of people aged over 85}} \; (\underline{\textbf{Index 100 in 2011}})$




#### Breakdown of people aged over 85




Source: STATBEL, Population by age at 01.01.2011

Insufficient offer
Low representativity of
the commercial sector

#### Market share of the Private Commercial Sector



#### Geographical breakdown of beds: 135,000 beds




Source: INAMI, list of nursing homes at 04.01.2013


## **Dynamic region**

High purchasing power

#### Average annual per capita income



#### Geographical breakdown of Belgium GDP



Source: STATBEL, 2012 income and Eurostat



## **ORPEA Belgium focuses its development in Flanders**


Strategic acquisition of 900 beds

- 300 beds operational located in Antwerp (3 facilities)
- 600 beds to be built in Antwerp: opening in 2015 and 2016

A pipeline of 1,500 beds under construction or refurbishment



A growing market share of Flanders in ORPEA Belgium network





# **Example of projects in Flanders**







**Knokke Le Zoute - 110 beds** 



De Haan - 80 beds



Edegem - 110 beds




Shoten - 125 beds






# **ORPEA** network

## **European leader: 40,374 beds at over 431 facilities**



Europe	Nbr of beds
Open beds	31,726
Beds under refurbishment	3,246
Beds under construction	5,402
Total	40,374

#### $\underline{Geographical\ breakdown\ of\ the\ network}$

















# A secured pipeline of 8,648 beds

#### **Network development over 10 years**



#### Ramp-up in mature facilities





## France: 339 facilities for 29,477 beds

# Openings of 2012: 20 facilities (1,900 beds)

- Strategic locations: 50% in Ile-de-France and Provence Alpes Cote d'Azur
- Refurbishment and creation of new facilities

# Development since start 2012: 887 new beds

- Licence for 1 facility of 84 beds
- \* Value added acquisitions

France	Nbr of beds
Open beds	24,154
Beds under refurbishment	2,334
Beds under construction	2,889
Total	29,477





29,477 beds in France, including 18% under construction or refurbishment



# **International:** 92 facilities for 10,897 beds

	Activity during 2012	Beds in operation	Beds under development	Total		Prospects
SPAIN	Acquisition and integration of Artevida (1,156 beds and places)	2,938 beds	n/a	2,938 beds 22 facilities	若	Acquisition opportunities on attractive terms in major cities
BELGIUM	Acquisition of 100% of Medibelge Opening of 1 120-bed facility (Brussels) Selective acquisitions	3,598 beds	2,920 beds	<b>6,518 beds</b> 56 facilities	半	New licences Selective acquisitions
ITALY	Opening of 180-bed facility (Trofarello) Acquisition of 200 beds	871 beds	405 beds	<b>1,276 beds</b> 12 facilities	* *	New licences Selective acquisitions
SWITZERLAND	End of work on the post-acute & rehabilitation care facility	165 beds	n/a	165 beds 2 facilities	茶	Ramp-up in the rehabilitation care facility



10,897 beds outside France, including 25% under construction or refurbishment







# **2012 Full-Year results**

# **2012:** increase in profitability

# **2012 INITIAL TARGET 2012 ACHIEVEMENTS** €1,429m **Revenues: €1,425m** +15.8% **Strong organic growth** +8.2% **Recurring EBIT margin: 13.6% Higher profitability** + 40 bp €300m **Property sales on attractive terms** (Selling price)




## Steep rise in 2012 revenue: +15.8%

2012	2011	%
1,227.3	1,094.5	+12.1%
86%	89%	
201.8	139.6	+44.5%
14%	11%	
105.6	67.5	
48.7	30.5	
32.2	26.8	
15.4	14.8	
1,429.1	1,234.1	+15.8%
	1,227.3 86% 201.8 14% 105.6 48.7 32.2	1,227.31,094.586%89%201.8139.614%11%105.667.548.730.532.226.815.414.8

Strong organic growth in 2012 +8.2% (Approx. €100m)

Strong increase abroad: +44.5% (Medibelge, Artevida)

#### **Historical revenue growth:**



CAGR on 2001 – 2012: +24.5%



# **Strong increase in all profitability indicators**

In €m	2012	2011	%
Revenues	1,429.1	1,234.1	+15.8%
EBITDAR (Recurring EBITDA before rents)	368.5	311.4	+18.4%
Recurring EBITDA	256.3	218.2	+17.5%
Recurring EBIT (Rec. Operating Profit)	193.7	163.2	+18.7%
EBIT (Operating profit)	222.2	190.0	+16.9%
Net financial income/(expense)	-72.8	-65.0	(+12.0%)
Profit before tax	149.4	125.0	+19.5%
Net profit (Group share)	97.0	80.3	+20.8%






## **Impact of new tax laws in France**



**Tax on value added (CVAE and CFE):** + **€4.4m** (€23m in 2012 compared with €6.7m in 2007)





New tax on dividend: + €0.8m

Amended Finance Law of 16 August 2012



Non deductibility of financial cost: + €2.5m

Finance Law of December 2012



Increase in the Corporate tax rate (34.43% to 36.10%): + €1.9m




# Rise in operating profitability

In €m	2012	2011	%
Revenues	1,429.1	1234.1	+15.8%
Staff costs	-715.8	-625.0	+14.5%
Expenses	-277.2	-240.8	+15.1%
Taxes and duties	-67.5	-58.4	+15.5%
Other income and expenses	-0.1	1.4	N.S.
<b>EBITDAR</b> (Recurring EBITDA before rents)	368.5	311.4	+18.4%
% of revenues	25.8%	25.2%	
Rents	-112.2	-93.1	+20.5%
Recurring EBITDA	256.3	218.2	+17.5%
% of revenues	17.9%	17.7%	
Depreciation & Amortisation	-62.7	-55.1	+13.8%
Recurring EBIT (Rec. Oper. Profit)	193.7	163.2	+18.7%
% of revenues	13.6%	13.2%	
Non-recurring items	28.5	26.8	N.S.
EBIT (Operating profit)	222.2	190.0	+16.9%



## **Trend in rents**

#### **¾** Rents in **€**m





Average annualised increase in rents: +1.6%

# Geographical breakdown of profitability

	2012			2011		
In €m	Rev.	Recurring EBITDA	% of Rev.	Rev.	Recurring EBITDA	% of Rev
France	1227.3	230.6	18.8%	1094.5	200.5	18.3%
Belgium	105.6	13.1	12.4%	67.5	10.2	15.1%
Spain	48.7	6.1	12.6%	30.5	1.8	6.0%
Italy	32.2	2.3	7.2%	26.8	1.9	7.2%
Switzerland	15.4	4.2	27.2%	14.8	3.8	25.7%
International	201.8	25.8	12.8%	139.6	17.8	12.7%
Grand TOTAL	1429.1	256.3	17.9%	1234.1	218.2	17.7%

Recurring EBIDTA: Recurring operating profit before depreciation and amortisation



# **Solid financial structure**

In €m	31-Dec-12	31-Dec-11
Non-current assets	4,151	3,757
Goodwill	380	323
Intangible assets	1,278	1,129
Property, plant & equipment and property under development	2,404	2,217
Other non-current assets  Current assets	89	88
<b>Current assets</b>	619	604
Of which cash, cash equivalents and marketablle securities	362	309
Assets held for sale	121	121
TOTAL ASSETS	4,891	4,482
Sh. equity, Group share and permanent deferred taxes	1,577	1,477
Shareholders' equity Group share	1,209	1,152
Deferred taxes on intangible assets (quasi equity)	369	325
Non-controlling interests	1	3
Non-current liabilities Other deferred tax liabilities Provision for liabilities and charges Long-term financial debt	2,038	1,817
Other deferred tax liabilities	321	314
Provision for liabilities and charges	57	42
Long-term financial debt	1,660	1,462
Current liabilities	1,153	1,064
Of which short-term debt (bridge loans)	504	466
Debt linked to assets held for sale	121	121
TOTAL LIABILITIES	4,891	4,482



# **Optimisation of the Group's finances**

#### 2012: arrangement of private placements

- **Objectives**: diversify sources of financing and extend the maturity of debt on attractive terms
- **Schuldschein** (€35m) with a 5-year maturity (due 2017)
- **Examples of Euro private placements** in several tranches:
  - Maturities: 5-year (€85m), 6-year (€20m) and 6.5-year (€128m)
  - Coupons: 4.10% over 5 years, 4.20% over 6 years and 4.60% over 6.5 years

		2011	2012
1	Diversification	% of non-bank debt = <b>11%</b>	<b>7</b> 29%
2	Extension of debt maturity	Average maturity = <b>4.1 years</b>	<b>7</b> 5.0 years
3	Greater flexibility	Restated financial leverage = <b>2.2</b>	<b>¥</b> 1.7



### Flexible financial structure

Metrics	31-Dec- 2012	30-June- 2012	31-Dec- 2011
Net debt*	1,802	1,756	1,619
Restated financial leverage <sup>1</sup>	1.7	2.1	2.2
Restated gearing <sup>2</sup>	1.2	1.3	1.2

<sup>\*</sup>Excluding €121m in debt linked to assets held for sale


#### **Banking covenants met comfortably**



#### Kerning Change in restated financial leverage



#### Change in restated gearing






Net debt - Real estate debt
EBITDA - (6% of Real estate debt)

Net debt
Shareholders' equity + quasi equity

## Solid financial structure

#### \* Debt maturity profile (excl. bridge loans)



# Bridge loans = financing for property under construction

- €122m over 4 years
- Converted into:
  - Property lease if ORPEA remains owner
  - Cash if the asset is sold to investors

#### Breakdown of the debt net

# Real estate debt €1,532m

- Financial property leases & long-term loans for operating real estate (€1,197m)
- Bridge loans for assets under construction (€335m), secured by:
  - Financial property lease if ORPEA remains owner
  - Sale to investors



#### **Debt hedging**

# PROPORTION OF THE DEBT HEDGED AT FIXED RATE

- \* Approx. 90% in 2013
- \* Approx. 95% from 2014 to 2017



Currently being audited

# **Operations: securing future growth**

#### **ASSETS**

#### **LIABILITIES**













- Network of 40,374 beds
  - 31,726 open beds in operation
  - 3,246 open beds under refurbishment
  - 5,402 beds under construction

- Financed by medium-term 5- to 7year loans
- No significant installments ahead: amortising loans
- Hedged by derivatives: fixed-rate swaps



Value of intangible assets (licences):

€1,278m



**Net operating debt:** 

€270m



Network of high-potential beds, partially valued as assets

The licences awarded are not valued on the balance sheet



# **Increase in real estate portfolio value\* to €2.4b**


	31-Dec-11	31-Dec-11	Change
Number of buildings	248	230	+18 build.
Of which fully owned	142	141	n.s.
Built surface area (in sqm)	824,000	756,000	9%
Total value (€m)	2,404	2,217	8%
Of which assets in operation	2,069	1,835	13%
Of which assets under construction	335	382	-12%

<sup>\*</sup> Excluding €121m in assets held for sale

#### **FEATURES**

- **¾** Average age < 10 years
- \* Strategic locations
- **Value per sqm: €2,510**

#### **Trend in the value of the real estate portfolio\* (€m)**





## **Cash flow statement**

2012	2011	H2 2012	H1 2012
256	218	134	122
208	202	130	78
26	-102	54	-28
-274	-226	-87	-187
300	124	141	159
234	101	184	50
-296	-248	-144	-152
-153 -143	-166 -82	-87 -57	-66 -86
115	180	102	13
53	33	142	-89
	256 208 26 -274 300 234 -296 -153 -143 115	256       218         208       202         26       -102         -274       -226         300       124         234       101         -296       -248         -153       -166         -143       -82         115       180	256       218       134         208       202       130         26       -102       54         -274       -226       -87         300       124       141         234       101       184         -296       -248       -144         -153       -166       -87         -143       -82       -57         115       180       102

<sup>&</sup>lt;sup>1</sup> Net cash flow from internal investing activities: investments in construction required for maintenance and to harness the growth pipeline, net of disposals and excluding acquisitions



<sup>&</sup>lt;sup>2</sup> Internal cash flow = Net cash flow from operating activities + Net cash flow from internal investing activities

## Increase in the dividend per share

**Froposed dividend to the 2012 AGM: €0.60 / share** 



Increase in the dividend per share + 20%

Share yield\*
2%

\*Based on the closing price of the share at 22 March 2013

Payout ratio of the net profit 33%





# **Strategy and outlook**

**Yves Le Masne –** Chief Executive Officer **Dr Jean-Claude Marian M.D. –** Chairman

# Openings of 2012: 2,150 beds and 1,300 jobs created



















Boussy St. Antoine (91), Nursing Home - 80 beds



St. Maur des Fossés (94), Nursing Home - 80 beds



Berlaimont (59), Nursing Home- 75 beds



Saintry (91), Nursing Home - 80 beds



# Openings of 2013: 2,000 beds and 1,200 jobs created



Guérande (44), Nursing Home - 80 beds



Espira d'Agly (66), Nursing Home - 70 beds



La Garenne Colombes (92), Nursing Home - 103 beds



Lyon Champvert (69), Psy. facility. - 179 beds



Le Cannet (06), Nursing Home-120 beds



Batz sur Mer (44), Nursing Home - 48 beds



Chamalières (63), Post-acute facility - 90 beds



Saint Sulpice de Royan (17), Nursing Home - 84 beds



Cateau Cambresis (59), Nursing Home- 94 beds



Meyzieu (69), Post-acute facility - 104 beds



Parmain (95), Nursing Home - 70 beds



Nyon (Suisse), Post-acute facility - 90 beds



# **2013: continued growth and cash flow strategy**

#### **STRATEGY**

Value added development





Fipeline comes on stream: 8,648 beds

Property sales at attractive conditions

#### **OUTLOOK**

Strong **increase in revenue** and solid organic growth

2013 target: €1,600m (+12%)

- \* Increase in profitability
- **Debt under control**
- \* Attractive dividend policy








# **Appendices**

# **Shareholding structure and Governance**

#### \* Shareholding structure (% of capital)



#### **Board of Directors**

- Dr Jean-Claude Marian Chairman
- Yves Le Masne CEO
- Brigitte Michel
- Alexandre Malbasa
- Jean Patrick Fortlacroix
- **FFP Invest** (Thierry Mabille de Poncheville)
- NEO-GEMA (Philippe Austruy)



## French nursing home sector


Low market share of the private sector

- Fublic and non-profit operators: reduction in investment capacity
- Private sector: investment capacity and job creation
- Reminder: in the UK, the market share of the private sector is 70%

# Breakdown of beds by type of operator



Fragmented private commercial sector



Source: Mensuel des Maisons de retraite, January 2013

<sup>\*</sup> As at 01.03.13 ORPEA had a total of 40,374 beds (29,477 beds in France and 10,897 beds abroad), including post-acute, rehab. and psychiatric beds



28,000

# **Strong solvency position of people aged 85+**

#### Comparison of nursing home cost vs. wealth

Average cost of nursing home for a resident

**€46,200** 

#### **Assumptions:**

- <sup>\*\*</sup> Average cost: €2,200 per month
- \* Average length of stay: 21 months

Average wealth of people aged 85+

**€135,000** 


Source: IGAS 2010 report: €110,000 to €160,000

#### **Income of elderly**

Average pension (excluding other income): €1,300 per month with wide disparities



- **■ €1,250 - €2,250**
- **■** > €2,250



#### Trends in income of the elderly by age bracket



Source: Report by Jean De Kervasdoué, Professor of Health Services Economics and Management, CNAM



#### **Stock market information**

#### \* Market data (last 12 months):

Average daily volume: 78,140 shares (= €2.3m)

– Price: €32.40

– High (12-month): €34.00

– Low (12-month): €24.20

**Turnover:** 38% in 12 months

Market cap.: €1,717m

Number of shares: 52,998,062



#### **Indices:**

- Compartment A of Euronext Paris, NYSE Euronext
- Member of CAC Mid 60 and SBF 120
- Member of SRD



#### Contacts:

ORPEA - Yves Le Masne, CEO

Steve Grobet, Investor Relations, Tel.: +33 (0)1 47 75 74 66, s.grobet@orpea.net

